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Abstract We observed recently1 that placental leptin is
markedly increased in preeclampsia. Since this disorder is
associated with vascular disorders, we have tested the hypothesis
that hypoxia regulates leptin expression. We show that hypoxia
increased leptin mRNA and secretion in trophoblast-derived
BeWo cells. This effect was mediated through leptin promoter
activation. 5P deletion analysis allowed us to delineate two
regions containing 1.87 kb and 1.20 kb of the promoter
which conferred respectively high and low responsiveness to
hypoxia. These data indicate that leptin is up-regulated by
hypoxia through a transcriptional mechanism likely to involve
distinct hypoxia-responsive cis-acting sequences on the
promoter. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Leptin, the protein product of the ob gene, regulates body
weight homeostasis by controlling food intake through its
hypothalamic receptors [1^3]. The leptin gene is expressed in
a restricted number of tissues. In the adult, the major source
of leptin is the adipose tissue and circulating levels are propor-
tional to fat mass [4]. Another leptin-producing organ is the
placenta [5]. During pregnancy, leptin concentration gradually
increases in maternal blood, out of proportion with change in
adipose tissue mass, and drops abruptly after delivery [5,6].
These observations suggest that leptin is released in the ma-
ternal circulation from the placenta. In support, recent data
obtained in dually perfused human placenta indicate that 95%
of placental leptin is released into the maternal circulation
[7,8]. The rate of placental leptin production amounts 115
ng/min, representing 14% of the estimated whole-body leptin
production [9]. This points out the placenta as an important
site of leptin production in humans.
Placental leptin mRNA [10] and protein [11] are markedly
increased in preeclampsia, a disorder associated with maternal
hypertension, reduction in placental blood £ow and placental
hypoxia [12]. This raises the hypothesis that decreased oxygen
tension is a positive regulatory factor of leptin gene expres-
sion. In the present study, we examined this proposal by as-
sessing the e¡ect of hypoxia in human trophoblast-derived,
leptin-expressing cells (BeWo). Our data show that leptin
gene expression is up-regulated under hypoxic conditions
and that this e¡ect is mediated through activation of distinct
cis-acting sequences of the human promoter.
2. Materials and methods
2.1. Cell cultures
JAr, JEG and BeWo cells were obtained from ATCC (Rockville,
MD, USA) and cultured in DMEM (JAr and JEG) or RPMI 1640
medium (BeWo) supplemented with 10% fetal calf serum and anti-
biotics. Fetal calf serum and culture media were purchased from Gib-
co BRL (Gaithesburg, MD, USA). Hypoxic conditions were applied
by placing the culture dishes in a sealed jar containing an oxygen
chelator (Oxoid Ltd, Basingstoke, UK). According to the manufac-
turer, an atmosphere with 6% O2 and 12% CO2 is achieved in the jar
within 1 h after sealing. Chemical hypoxia was produced by adding
cobalt chloride (CoCl2) or desferrioxamine (DFO) (Sigma, St Louis,
MO, USA) to the culture medium. Both agents were dissolved in
water and added to the medium to achieve a ¢nal concentration of
50 WM. After various time in culture as indicated, cells and culture
medium were harvested and separately frozen until use. Leptin was
determined in the medium by radioimmunoassay, as described by the
manufacturer (Linco Research, St. Charles, MO, USA).
2.2. Immunocytochemistry
BeWo cells were seeded on 15-mm glass slides placed in 6-well
plastic plates and grown to 60^70% con£uence. Fixation was carried
out for 45 min at room temperature in 4% PBS^paraformaldehyde.
Cells were washed in PBS prior to addition of the leptin antibody
(kind gift of Dr. S.D. Holmes, SmithKline-Beecham, Harlow, UK).
The primary antibody was added for 30 min, followed by sequential
10-min incubations with solutions of biotinylated second antibody,
streptavidin-peroxidase and the substrate AEC chromogen (3-ami-
no-9-ethylcarbazole in N,N-dimethylformamide). Negative staining
was performed by omitting the primary antibody. A counterstaining
was performed with Mayer’s hematoxylin. Sections were photo-
graphed using a Leitz Dialux 22 microscope (Leitz, Wetzlar, Ger-
many).
2.3. Northern blot analysis
Total RNA was extracted with 4.4 M guanidine thiocyanate [13]
and analyzed by Northern blotting after electrophoresis in 1.2% form-
aldehyde agarose gel, transfer and ¢xation onto nitrocellulose ¢lters
(Hybond-N+, Amersham Pharma Biotech Inc, Piscataway, NJ, USA).
Hybridization was performed with a human GLUT3 cDNA (kind gift
of Dr. G. Bell, Chicago, IL, USA) and a ribosomal 18S probe for
control of RNA loading. Blots were subjected to autoradiography and
image analysis (Perfect-Image, Numeris, Nanterre, France).
2.4. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Complementary DNA was synthesized at 37‡C for 50 min from 500
ng total RNA using random hexanucleotides primers (Amersham
Pharmacia Biotech Inc, Piscataway, NJ, USA) and Moloney murine
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leukemia virus reverse transcriptase (Superscript II, Life Technologies
SARL Cergy Pontoise, France). Brie£y, 100 ng of reverse-transcribed
RNA was ampli¢ed with 2.5 U Taq polymerase in 20 mM Tris^HCl
(pH 8.0), 50 mM KCl, 1 mM MgCl2, 0.2 mM dNTP and 0.5 WM of
gene-speci¢c sense and antisense primers. The PCR products were
visualized on 2% agarose gels by ethidium bromide staining and ex-
posed to UV transilluminator for photography (Perfect-Image, Nu-
meris, Nanterre, France). The primer pair derived from the human
leptin cDNA sequence [1] was as follows: upstream primer
5P-CATTGGGGAACCCTGTGCGGATTC-3P ; downstream primer
5P-TGGCAGCTCTTAGAGAAGGCCAGC-3P. Ampli¢cation con-
sisted of one cycle at 94‡C for 2 min, followed by 30 cycles at 94‡C
for 30 s, 60‡C for 1 min and 68‡C for 2 min, with a ¢nal extension
step at 68‡C for 7 min. This ampli¢ed a fragment of 348 bp. The
primer pair derived from the mouse L-actin cDNA sequence [14] was
as follows: upstream primer 5P-GAGACCTTCAACACCCC-3P ;
downstream primer 5P-GTGGTGGTGAAGCTGTAGCC-3P. Ampli-
¢cation consisted of one cycle at 94‡C for 2 min, followed by 30 cycles
at 94‡C for 40 s, 62‡C for 40 s and 74‡C for 1 min, with a ¢nal
extension step at 74‡C for 7 min. This ampli¢ed a fragment of 236 bp.
2.5. Transient transfections
Epididymal rat adipose cells were isolated and transfected by elec-
troporation as described in [15]. For BeWo cells, Lipofectamine0-
mediated transfection (Gibco BRL, Gaithesburg, MD, USA) was
performed according to manufacturer’s recommendations, when cells
have reached approximately 50% con£uence. After 5 h, the medium
was changed and the cells were cultured for 24 h in normoxic or
hypoxic conditions. Activity of the human leptin promoter was as-
sessed using a series of luciferase reporter constructs (kind gift of
J. Auwerx), containing serial 5P deletions extending from 32.38
(v2), 31.87 (v5), 31.20 (v14), 30.98 (v12), and 30.17 (v4) kb up-
stream of the transcription initiation site [16,17]. pGL3-Basic vector
(Promega Corp. Madison, WI, USA) was the negative control. To
normalize for transfection e⁄ciency, a pRSV-L-galactosidase expres-
sion vector was co-transfected with each construct. Transfections were
performed at least in triplicate with di¡erent plasmid preparations. In
each experiment, individual data were calculated as mean of replicates
and expressed as the ratio of luciferase over L-galactosidase activity.
Luciferase assays were carried out as described [15].
2.6. Preparation of nuclear extract
Nuclear extracts were prepared essentially as previously described
[18]. Brie£y, con£uent BeWo cells were broken in a dounce homoge-
nizer in 10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5
mM dithiothreitol, 0.05% Triton X-100, and protease inhibitor mix-
ture containing 20 WM leupeptin, 20 WM pepstatin, 2 WM aprotinin, 50
WM AEBSF, 50 mM NaF, and 2 mM sodium metavanadate. Nuclei
were pelleted by 10 min centrifugation at 600Ug, at 4‡C. The nuclear
pellet was then resuspended in 100 Wl of hypotonic bu¡er (25% glyc-
erol, 20 mM HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 1.2 M KCl and
protease inhibitors). Nuclei were allowed to swell for 30 min at 4‡C
and a clear nuclear extract was obtained by centrifugation 30 000Ug,
30 min at 4‡C. Proteins were assayed by the Bio-Rad protein assay
procedure (Richmond, CA, USA), with bovine serum albumin as
standard.
2.7. Western blotting analysis
Nuclear proteins from BeWo cells were subjected to sodium dodec-
yl sulfate^polyacrylamide gel electrophoresis using a 7.5% resolving
gel, and electroblotted onto nitrocellulose membrane (Hybond ECL,
Amersham Pharma Biotech Inc, Piscataway, NJ, USA). Following
blocking with low-fat milk, membranes were incubated for 1 h with
an anti-hypoxia-inducible factor-1 K subunit (HIF-1K) antiserum [19]
(kind gift of J. Pouysse¤gur). The blots were washed and exposed for
1 h to horseradish peroxidase-conjugated anti-rabbit IgG. The im-
mune complex was detected by luminescent visualization (ECL,
Amersham Pharma Biotech Inc, Piscataway, NJ, USA) on X-ray
¢lm (Kodak Biomax MR). As a control of nuclear extract integrity,
the membrane was stripped and blotted with an anti-Sp1 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA).
2.8. Statistical analysis
Data (mean of replicates) are mean þ S.E.M. for the indicated num-
ber of experiments. Statistical analysis was performed using Student’s
t-test for unpaired data with signi¢cance de¢ned as P6 0.05.
3. Results
A ¢rst series of time course experiments were conducted to
assess the capacity of trophoblast-derived cell lines to produce
leptin in culture. Among JAr, JEG and BeWo cell lines, only
the latter released consistent amounts of leptin (Fig. 1A). In
these cells, the rate of leptin secretion was stable around 0.2
ng/106 cells/24 h over 5 days in culture. Moreover, leptin was
readily detected by immunocytochemistry (Fig. 1B). There-
fore, the BeWo cells were chosen as a physiological relevant
model to assess placental leptin production.
To assess the e¡ect of hypoxia, BeWo cells were exposed to
either low oxygen (6%) or chemical hypoxia induced by CoCl2
or DFO for various periods of time. Induction of the glucose
transporter GLUT3 mRNA was ¢rst measured to assess the
cell responsiveness to hypoxia, since this transporter has been
Fig. 1. Leptin production in trophoblast-derived cell lines. A: Lep-
tin secretion in JEG, JAr and BeWo cells. Cells were cultured in
normoxia for 120 h. The culture medium was sampled at the indi-
cated period of time to measure leptin by radioimmunoassay (Linco
Research, St. Charles, MO, USA). B: Immunodetection of leptin in
BeWo cells. Immunostaining was carried out with a speci¢c anti-
body for leptin (A, C), followed by biotinylated second antibody,
streptavidin-peroxidase and the substrate AEC chromogen (3-ami-
no-9-ethylcarbazole in N,N-dimethylformamide). Negative staining
was performed by omitting the primary antibody (B). A counter-
staining was performed with Mayer’s hematoxylin. Magni¢cations
are 595 (A), 425 (B) and 425U (C).
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previously shown to be induced under hypoxic stimuli in hu-
man trophoblast in culture [20]. In comparison with untreated
(basal) cells, both low O2 and chemical hypoxia-induced by
CoCl2 increased GLUT3 mRNA after 24 h (Fig. 2A). Sim-
ilarly, leptin mRNA and leptin release were increased under
exposure to hypoxic conditions (Fig. 2B,C). The e¡ect of hyp-
oxia on the amounts of leptin in the culture medium was
detectable only after 48 h (data not shown), whereas leptin
mRNA was increased after 4 to 8 h (Fig. 2B). This lag time
between leptin mRNA induction and increased leptin release
suggests a transcriptional e¡ect of hypoxia.
To test this hypothesis, the e¡ect of hypoxia was studied on
the human leptin promoter. The activity of serial deletions
extending from 32.38 to 30.17 kb upstream of the leptin
gene transcription start site was assessed. The longest frag-
ment, v2, included a region previously characterized as a pla-
cental enhancer (PLE) [21,22], whereas shorter fragments of
the promoter were deleted of this domain. As shown in Fig. 3,
absence of the PLE in v5 and v4 fragments led to a marked
decrease in promoter activity in the BeWo cells. Nevertheless,
the luciferase activity driven by these promoter sequences re-
mained markedly higher (more than 25-fold) than the lucifer-
ase activity measured in cells transfected with the promoter-
less parent vector (basic). In contrast to the BeWo cells,
deletion of the PLE did not signi¢cantly alter the luciferase
activity measured in transfected adipose cells. These results
con¢rm previous observations [22] and strengthen the physio-
logical relevance of the cellular model used in the present
study.
In comparison with basal conditions, the activity of the v2
promoter fragment increased by more than 4-fold under hy-
poxic conditions (Fig. 4). Deletion of the PLE did not pre-
clude the e¡ect of hypoxia. Rather, the stimulatory e¡ect of
hypoxia tended to be larger on v5 than on v2 promoter frag-
Fig. 2. E¡ect of hypoxia on GLUT3 and leptin in BeWo cells. The
BeWo cells were cultured to con£uence and exposed to 6% O2 or
chemical hypoxia induced by CoCl2 (50 WM) or DFO (50 WM). At
the end of the culture, total RNAs were extracted. A: Expression of
GLUT3 mRNA and 18S rRNA was analyzed by Northern blotting.
The blot shows signals arising from cells cultured for 24 h in nor-
moxia (basal) or hypoxic conditions. B: Expression of leptin and
actin mRNA was analyzed by RT-PCR after di¡erent periods of
time as indicated. C: Leptin was measured in the culture medium
by radioimmunoassay after 48 h. *P6 0.05 versus basal (n = 5).
Fig. 3. Activity of the human leptin promoter in adipose and BeWo
cells. Primary rat adipose cells were transfected by electroporation
with 5 Wg of luciferase reporter constructs, either promoterless (ba-
sic) or containing various lengths of the human leptin promoter
(v2: 32.38 kb and v5: 31.87 kb). BeWo cells were transfected by
lipofection with 0.5 Wg of the same constructs. A pRSV-L-galactosi-
dase expression vector was co-transfected with each construct. Lucif-
erase activity was assessed after 24 h. Data represent the luciferase
normalized to L-galactosidase activity and are the mean þ S.E.M.
for four (adipose) to seven (BeWo) independent experiments.
*P6 0.05 versus v2; ns, non-signi¢cant versus v2.
Fig. 4. E¡ect of hypoxia on human leptin promoter activity in
BeWo cells. BeWo cells were transfected as in Fig. 3 and exposed
to normoxia (basal) or various hypoxic conditions: 6% O2, DFO
(50 WM) or CoCl2 (50 WM) for 24 h. The 5P end of leptin promoter
deletions are: v2: 32.38, v5: 31.87, v14: 31.20, v12: 30.98, and
v4: 3017 kb. Data represent the ratio of hypoxic/basal expression
for each construct and are the mean þ S.E.M. of 5^7 independent
transfections. *P6 0.05 versus v5; ns, non-signi¢cant versus v5.
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ment activity. Depending of the stimulus, the luciferase activ-
ity driven by the v5 deletion was enhanced by 7 to 12-fold.
This demonstrates that the human leptin promoter is induc-
ible by hypoxia and that this e¡ect is mediated by the ¢rst
1.87 kb of the promoter, which do not contain the PLE.
Shorter fragments (v14, v12 and v4) were also inducible by
hypoxia, but the ratio of hypoxic/normoxic expression of
these constructs reached at most 3-fold.
HIF-1K is induced in response to hypoxia through inhibi-
tion of ubiquitin-mediated proteasome degradation [23]. To
determine whether this process occurred in the BeWo cells
under the conditions used in this study, we prepared nuclear
extracts to assess HIF1K by western blotting analysis. As
shown in Fig. 5, HIF1-K was markedly induced after 4 and
8 h of exposure to CoCl2 or DFO. This e¡ect was speci¢c to
HIF-1K, as suggested by the constitutive expression of the
transcription factor Sp1 in the same extracts.
4. Discussion
It is established that the human placenta produces signi¢-
cant amounts of leptin [7,8], resulting in increased circulating
levels in the maternal blood. The physiological role of this
hormonal change has yet to be clari¢ed, since it does not
lead to a reduction in food consumption by the mother. We
have recently demonstrated that the placenta expresses func-
tional leptin receptors [24]. This suggests that leptin might
also exert a local autocrine e¡ect in this organ.
The regulation of leptin gene expression has been exten-
sively studied in the adipose cells, but is less well characterized
in cells of placental origin. Leptin mRNA and protein are
markedly increased in placenta of insulin treated type I dia-
betic mothers, suggesting that insulin modulates expression of
placental leptin [25]. Preeclampsia is another pathological sit-
uation associated with enhanced placental leptin [10,11]. Since
preeclampsia is characterized by placental hypoxia, this raised
the hypothesis that low oxygen could be a regulatory factor of
leptin gene expression. The present study was designed to
explore this proposal in a relevant cellular model. The tropho-
blast-derived BeWo cells were chosen since they both produce
leptin in culture and are responsive to hypoxia, as demon-
strated by increased GLUT3 gene expression.
The e¡ect of hypoxia can be mimicked by various agents
including transition metal ions, such as cobalt, and iron che-
lating agents, such as DFO. Although their mechanism of
action is not fully understood, these factors are thought to
alter the function of a putative heme protein participating
to a O2 sensor system [26]. These agents mimic the e¡ect of
hypoxia on the expression of a number of hypoxia-inducible
genes, including erythropoietin, the GLUT1 isoform of glu-
cose transporter and vascular endothelial growth factor
(VEGF) [26^29].
A major ¢nding of this study is that hypoxia induced either
by low O2, DFO or CoCl2 markedly increases the activity of
the human leptin gene promoter in placental cells. Deletion
analysis allowed to map a domain encompassing the ¢rst 1.87
kb of the leptin promoter which conferred high responsiveness
to hypoxic conditions. Exclusion of the PLE from this domain
indicates that the trans factors involved are distinct from
those, of yet unidenti¢ed nature, which bind to the PLE
[21,22]. Transcription of hypoxia-inducible genes is regulated
by hypoxia response elements (HREs) which contain binding
sites for HIF-1. This transcription factor is composed of HIF-
1K and HIF-1L (ARNT) subunits [30]. HIF-1K is rapidly de-
graded by the ubiquitin^proteasome pathway in normoxia
and this process is inhibited by hypoxia, allowing dimerization
of HIF-1K with HIF-1L in the nucleus [23]. The HRE of the
VEGF promoter has been shown to be composed of a HIF-1
binding site and a downstream ancillary sequence, forming an
imperfect inverted repeat [31]. This consensus motif is con-
served among several hypoxia-inducible genes. Analysis of
the human leptin promoter revealed a similar structure (5P-
TACGTG-10 nt-CACAGA-3P), which is included in the 1.87-
kb promoter construct. Coupled with the marked induction of
HIF-1K by hypoxia, these observations argue for the implica-
tion of HIF-1 in leptin gene induction. Further studies are
underway to con¢rm that this promoter region is mediating
the hypoxic response.
The leptin promoter region extending from 31.20 kb to the
transcription initiation site does not contain consensus HRE
sequences. Nevertheless, it exhibited hypoxically inducible ac-
tivity. These observations raise the possibility that hypoxia-
dependent pathways target distinct cis-acting sequences on the
leptin promoter, as previously described for GLUT1 gene [27].
Interestingly, the placental production of several cytokines,
including TNFK, IL-1K and IL-1L, is increased under hypoxia
in cultured villous explants from human placenta. This does
not appear to be a general e¡ect, since IL-6 production is not
modi¢ed in the same model [29]. The authors suggest that
in£ammatory cytokines may contribute to the pathophysiol-
ogy of preeclampsia. Whether this is also the case for leptin
remains to be determined. Alternatively, since leptin is a po-
tent angiogenic factor [32,33], enhanced placental leptin pro-
duction could represent a compensatory response aimed at
favoring neo-vascularization, in concert with other factors
such as VEGF [34] and TGFL [35].
In conclusion, the present data show that the human leptin
gene is transcriptionally up-regulated by hypoxia. This e¡ect
is mediated by activation of distinct domains of the promoter
and is independent of the presence of the PLE.
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Fig. 5. E¡ect of hypoxia on HIF-1K in BeWo cells. The BeWo cells
were cultured for the indicated periods of time, in basal conditions
or in the presence of CoCl2 (50 WM) or DFO (50 WM). At the end
of the culture, nuclear extracts (20 Wg) were analyzed by SDS^
PAGE (7.5% gel) and immunoblotting using an anti-HIF-1K antise-
rum. The membrane was stripped and blotted with an anti-Sp1 anti-
body.
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